Table 2.
Summary of recent reported H2S-mediated CRC therapy.
| Therapeutic agent | Therapeutic strategy | Imaging method | Stimulus | Colon cancer cells |
|---|---|---|---|---|
| MSNP-N3-FA/DOX | Chemotherapy | – | H2S | HCT116; |
| HT-29 | ||||
| TP-HS | Chemotherapy | Fluorescence imaging | H2S | HCT116 |
| Ru-NBD | PDT | Fluorescence imaging | H2S; | HCT116 |
| Light | ||||
| MOF NPs | PDT | Fluorescence imaging | H2S; | HCT116; |
| Light | LoVo | |||
| TNP-SO | PDT | NIR imaging | H2S; | HCT116 |
| Light | ||||
| 12+-PSs-FA | PDT | NIR imaging | H2S; | HCT116; |
| NIR light | HT-29 | |||
| ZNNPs@FA | PDT | PA imaging | H2S; | HCT116 |
| Light | ||||
| Nano-PT | PTT | NIR-II imaging | H2S; | HCT116 |
| Ligh | ||||
| t | ||||
| Cu2O NPs | PTT | PA imaging | H2S; | HCT116 |
| NIR light | ||||
| Au@Cu2O | PTT | PA imaging | H2S; | HCT116 |
| NIR light | ||||
| Bi:Cu2O@HA | PTT | CT imaging | H2S; | CT26 |
| NIR light | ||||
| FeOOH NSs | PTT/Ferroptosis/Scavenging endogenous H2S | MRI imaging | H2S; | CT26 |
| NIR light | ||||
| PL-Cu | Chemotherapy/PTT | – | H2S; | HCT116 |
| NIR light | ||||
| N3-GT-CPT/ICG | Chemotherapy/PTT | NIR imaging | H2S; | CT26 |
| NIR light | ||||
| NPs@BOD/CPT | Chemotherapy/PTT | NIR-II imaging | H2S; | HCT116 |
| NIR light | ||||
| CatCry-AgNP-DOX | Chemotherapy/PTT | NIR-II imaging | H2S; | HCT116 |
| NIR light | ||||
| Cu-DhaTph COF | PDT/PTT | – | H2S; | HCT116 |
| NIR light | ||||
| FR-H2S | PDT/PTT | Fluorescence imaging | H2S; | HCT116 |
| Far-red light | ||||
| NP-Cu | PDT/PTT/CDT | – | H2S; | HCT116 |
| NIR light; | ||||
| Cu2O@CaCO3@HA | PDT/PTT/CDT/Calcium overload | – | H2S; | CT26 |
| NIR-II light; | ||||
| pH | ||||
| 5-Fu/Cur-P@HMPB | Chemotherapy/CDT/Autophagy | – | H2S | HCT116 |